|
普罗帕酮 莫雷西嗪 美西律的疗效和安全性再评价 |
| |
ts of nervous system in the mexiletine group and morcizine group than those in propafenone; (7) The occurrence of adverse reactions was not correlated with the blood levels of propafenone or moricizine, while higher blood levels of mexiletine accompanied with higher rates of adverse reactions. Conclusion Propafenone, moricizine and mexiletine are effective in the treatment of arrhythmias in patients not suffered from myocardial infarction. The long term effective rate is 60-70%, and there is no definite relationship between blood drug concentration and the efficacy of treatment with any of the 3 drugs. The arrhythmogenic effect was rarely observed in these patients. In contrast to the condition in CAST, the use of antiarrrhythmic drugs is relatively safe in patients not suffered from myocardial infarction.
上一页 [1] [2] [3]
上一个医学论文： 女性急性心肌梗塞的临床特点
下一个医学论文： 23名百岁老人垂体
|
|
|
|
|
|
|
您现在的位置： 绿色健康网 >> 医学论文 >> 内科论文 >> 正文